Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Denali Therapeutics Inc. (DNLI)
Price$22.28Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $105.1M | $48.7M | $335.6M | $26.3M | $129.1M | $0 | $0 |
| Research & development | $418.8M | $396.4M | $423.9M | $358.7M | $265.4M | $212.6M | $193.4M | $143.2M | $74.5M | $75.7M |
| Operating expenses | $555.3M | $501.9M | $527.2M | $449.2M | $344.4M | $272.9M | $239.9M | $175.5M | $90.1M | $87.4M |
| Operating income | −$555.3M | −$487.3M | −$196.7M | −$340.7M | −$295.8M | $62.7M | −$213.2M | −$46.4M | −$90.1M | −$87.4M |
| Operating margin | — | — | −59.51% | −324.32% | −607.83% | 18.69% | −809.97% | −35.92% | — | — |
| EBITDA | −$544.2M | −$479.5M | −$180.0M | −$330.4M | −$287.2M | $71.2M | −$205.2M | −$39.0M | −$87.1M | −$86.0M |
| EBITDA margin | — | — | −54.45% | −314.43% | −590.17% | 21.23% | −779.61% | −30.18% | — | — |
| Net income | −$512.5M | −$422.8M | −$145.2M | −$326.0M | −$290.6M | $71.1M | −$197.6M | −$36.2M | −$88.2M | −$86.7M |
| Net profit margin | — | — | −43.94% | −310.28% | −597.20% | 21.20% | −750.81% | −28.07% | — | — |
| Basic EPSper basic share | -$2.97 | -$2.57 | -$1.06 | -$2.60 | -$2.39 | $0.65 | -$2.07 | -$0.39 | -$5.89 | -$13.49 |
| Diluted EPSper diluted share | -$2.97 | -$2.57 | -$1.06 | -$2.60 | -$2.39 | $0.63 | -$2.07 | -$0.39 | -$5.89 | -$13.49 |
Owners
Reported shareholders
10.13%of listed shares
T. Rowe Price Investment Management, Inc.16.18M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
T. Rowe Price Investment Management, Inc. | 10.13%16.18M shares |
BlackRock, Inc. | 8.78%14.03M shares |
BAILLIE GIFFORD & CO | 7.49%11.96M shares |
STATE STREET CORP | 4.41%7.05M shares |
Temasek Holdings (Private) Ltd | 4.39%7.01M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.05%6.48M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.93%6.28M shares |
FMR LLC | 2.84%4.54M shares |
GOLDMAN SACHS GROUP INC | 2.60%4.16M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.49%3.97M shares |
Holocene Advisors, LP | 2.44%3.91M shares |
BAKER BROS. ADVISORS LP | 2.34%3.73M shares |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.98%3.16M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.96%3.14M shares |
UBS Group AG | 1.95%3.12M shares |
ALLIANCEBERNSTEIN L.P. | 1.87%2.98M shares |
DIMENSIONAL FUND ADVISORS LP | 1.79%2.86M shares |
NORGES BANK | 1.77%2.82M shares |
Pictet Asset Management Holding SA | 1.75%2.79M shares |
Capital Research Global Investors | 1.61%2.57M shares |
Percentages use 159.76M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 6, 2026Form 4 | Schuth Alexander O.COFO and Secretary | SellCommon Stock | 17.2K | $16.50 | $284.1K | 282.8K |
| Jan 6, 2026Form 4 | Watts Ryan J.President and CEO | SellCommon Stock | 35.2K | $16.50 | $580.8K | 296.8K |
| Dec 11, 2025Form 4 | BAKER JULIAN +5Director | Buy$0.01 Prefunded Warrants · derivative · indirect | 2.10M | $17.49 | $36.64M | 26.00M |
| Dec 11, 2025Form 4 | BAKER JULIAN +5Director | Buy$0.01 Prefunded Warrants · derivative · indirect | 190.5K | $17.49 | $3.33M | 2.34M |
| Aug 13, 2025Form 4 · 10b5-1 | Ho CaroleChief Medical Officer | SellCommon Stock | 806 | $14.64 | $11.8K | 216.6K |